Targeting Inflammation for Endometrial Cancer Prevention

Study Overview
=================
Brief Summary
-----------------
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase risk of endometrial cancer.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. To develop a model for a biobank that can be expanded across the Mayo Enterprise and implemented at extramural collaborative sites, including underserved populations. OUTLINE: Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.

Official Title
-----------------
Targeting Inflammation for Endometrial Cancer Prevention

Conditions
-----------------
Endometrial Carcinoma

Intervention / Treatment
-----------------
* Procedure: Biospecimen Collection
* Other: Questionnaire Administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women over the age of 18 years old undergoing hysterectomy for any benign indication or endometrial cancer Exclusion Criteria: Men Women under the age of 18 years Women with a history of cancer, except for endometrial cancer or non-melanoma skin cancer Women with type 1 diabetes Women that have received radiation or chemotherapy for cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (questionnaire, biospecimen collection)<br>Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery. | Procedure: Biospecimen Collection<br>* Undergo collection of blood, urine, and tissue samples<br>* Other names: Biospecimen Collected;Other: Questionnaire Administration<br>* Complete risk factor questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of eicosanoids and specialized pro-resolving mediators (SPMs) in visceral adipose tissue (VAT) | Will compare eicosanoid and SPM levels by case-control status with linear models, adjusted for age and body mass index (BMI) (and menstrual date, if needed). | Through study completion, up to 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ribonucleic acid (RNA) expression pathways related to inflammation in VAT | Will assess RNA data with cluster analysis and principal component analysis, focusing on inflammatory / immune pathways. We will assess RNA expression patterns in relation to eicosanoid / SPMs that discriminate cases versus controls. | Through study completion, up to 24 weeks |